Ikarian Capital
$611M 13F equity value
154 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Ikarian Capital covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| ABVX | ABIVAX SA | 328,635 | $43M | 7.1% |
| KOD | KODIAK SCIENCES INC | 1,059,730 | $41M | 6.8% |
| ALMS | ALUMIS INC | 870,548 | $24M | 4.0% |
| PRAX | PRAXIS PRECISION MEDICINES I | 72,842 | $24M | 4.0% |
| PCVX | VAXCYTE INC | 388,682 | $23M | 3.7% |
| ANIP | ANI PHARMACEUTICALS INC | 272,085 | $23M | 3.7% |
| CLDX | CELLDEX THERAPEUTICS INC NEW | 478,500 | $18M | 2.9% |
| RCUS | ARCUS BIOSCIENCES INC | 504,559 | $16M | 2.5% |
| RLMD | RELMADA THERAPEUTICS INC | 2,148,359 | $15M | 2.4% |
| CAPR | CAPRICOR THERAPEUTICS INC | 604,215 | $15M | 2.4% |
Track Ikarian Capital's 13F portfolio: $611M in reported holdings, 154 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}